Treatment of Fecal Incontinence Using Allogenic-Adipose-derived Mesenchymal Stem Cells: A Prospective, Dose Escalation, Randomized, Placebo-controlled, Parallel-group, Single-blind, Single-center Pilot Study
Overview
- Phase
- Phase 1
- Intervention
- ALLO-ASC injection
- Conditions
- Fecal Incontinence
- Sponsor
- Yonsei University
- Enrollment
- 21
- Locations
- 1
- Primary Endpoint
- Clinically measured abnormality of laboratory tests and adverse events
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
-
Purpose: The investigators aimed to investigate the safety and efficacy in the treatment of fecal incontinence by injection of ALLO-ASC into the anal sphincter.
-
Method
- Safety test of allogenic ASCs injection
- Efficacy test of allogenic ASCs injection
Detailed Description
* Background: Fecal incontinence is a distressing condition with recurrent uncontrolled passage of fecal material. Although fecal incontinence is developed by multifactorial causes, treatments were limited in medical or surgical methods. According to the recent studies of stem cell regeneration, it is reported that human adipose-derived stem cells have plentiful capacity in muscle regeneration, which had the efficacy to treat Crohn's fistulas. Therefore, the investigators hypothesized that the capability of muscle regeneration of allogenic-adipose-derived mesenchymal stem cells (ALLO-ASC) can be used to treat degenerated anal sphincter, which leads to fecal incontinence. * Purpose:The investigators aimed to investigate the safety and efficacy in the treatment of fecal incontinence by injection of ALLO-ASC into the anal sphincter. * Method 1. Safety test of allogenic ASCs injection In the first year, the investigators will investigate the safety of ALLO-ASC injection by a dose escalation study. Patients are sequentially enrolled into three groups, which are composed of three patients each. They are treated with an injection of ALLO-ASC to the anal sphincter for 3x107 cells/ml (group 1), 6x107 cells/ml (group 2), 9x107 cells/ml (group 3), respectively. After receiving the ALLO-ASC injection, patients will receive a physical examination, a serologic and immunologic response test (CD4/CD8) with an assessment of the Wexner score, patient satisfaction survey, WHO toxicity scale, adverse events, anorectal manometry and endorectal ultrasound at 1, 4, 8 weeks, 4, 6, 9, and 12 months in the outpatient clinic. The response of ALLO-ASC injection is assessed at 8 weeks after an injection and the most effective dose is determined among the groups. 2. Efficacy test of allogenic ASCs injection In the second year, the investigators will assess the efficacy of the ALLO-ASC injection comparing the ALLO-ASC injection group and the placebo group (0.9% normal saline injection) by a randomized, open-label, single-blind design. Each group is composed of six patients. Both the clinical assessment and follow-up period are identical with the first-year protocol.
Investigators
Eligibility Criteria
Inclusion Criteria
- •At least 19 years old
- •Patients who received either medical therapy or biofeedback for fecal incontinence for more than 2 months with Wexner score ≥ 8
- •Transanal ultrasonography: presents a continuous fashion of anal sphincter
- •Anal manometery: decreased anal pressures than normal level
- •Negative for urine β-hCG in the screening test
- •An informed consent form has been signed by the patient
Exclusion Criteria
- •Participation in another clinical trial within 30 days
- •History of anorectal surgery within the previous 6 months
- •History of malignant tumor surgery within the previous 5 years (except for carcinoma in situ)
- •Patients requiring anorectal surgical treatments
- •History of artificial sphincter surgery
- •History of vaginal delivery within 6 months
- •Medical history of variant Creutzfeld-Jakobs disease or related diseases
- •Allergy to bovine-derived materials, fibrin glue or anesthestics
- •Autoimmune disease
- •Active tuberculosis
Arms & Interventions
ALLO-ASC group
Allogenic-adipose-derived mesenchymal stem cell (ALLO-ASC) with fibrin glue injection to the anal sphincter
Intervention: ALLO-ASC injection
Normal saline group
0.9% normal saline with fibrin glue injection to the anal sphincter
Intervention: Placebo
Outcomes
Primary Outcomes
Clinically measured abnormality of laboratory tests and adverse events
Time Frame: one year (12 months)
The investigators will assess the safety of allogenic-adipose-derived mesenchymal stem cell (ALLO-ASC) injection to the anal sphincter among the three experimental groups (group 1: 3x107 cells/ml; group 2: 6x107 cells/ml; group 3: 9x107 cells/ml)).
Secondary Outcomes
- Satisfaction as measured by Wexner Score(one year (12 months))